ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia

NCT07106684 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma, Plasma Cell Leukemia

Interventions

PROCEDURE: Autologous hematopoietic stem cell transplantation
BIOLOGICAL: BCMA CAR-T
DRUG: GPRC5D/CD3 BiTEs

Sponsor

Institute of Hematology & Blood Diseases Hospital, China